About the journal

The Iranian Journal of Blood and Cancer (IJBC) serves as the prestigious official scientific quarterly journal of the Iranian Pediatric Hematology and Oncology Society (IPHOS). IJBC is accessible through online platforms, offering a remarkable compilation of scholarly manuscripts that delve into diverse dimensions of blood disorders and cancers. The journal warmly welcomes submissions of original papers, reviews, case reports, and letters to the Editor that revolve around the intricate realms of blood disorders and human malignancies. It is worth noting that the journal imposes no charges for manuscript submission, and authors are not subject to additional fees based on the length of their articles, inclusion of figures, or supplementary data.
View full Aims & Scope
Main Image

Iranian Journal of Blood and Cancer

2023، Volume 15، Number 4

Print ISSN: 2008-4595

Online ISSN: 2008-4609

Chairman: Mohammad Saeid Rahiminejad, MD

Editor-in-Chief: Hassan Abolghasemi, MD

Associate Editors: Davood Bashash, Ph.D ; Mohammad Faranoosh, MD

Artificial Intelligence (AI): The Next Stage of Evolution?
Humans have created AI to surpass the limits of comfort and improve their way of life. Through the integration of AI into machines, they have aimed to unlock unprecedented levels of convenience; however, now, we are at a stage where this important question arises: Who holds the upper hand? Do humans continue to hold dominion, or have AI-equipped machines taken the reins? I go a step further and pose my question from a more thoughtful standpoint: Friend or foe?

==========================================================================================================================================================================================================================================================================================

 Beyond human capacity: How artificial intelligence (AI) is enhancing cancer diagnosis and treatment
Ravari et al. have provided a succinct overview of the role of Artificial Intelligence (AI) in cancer research, specifically in the domains of diagnosis and treatment. The authors have presented a figure that illustrates the process of training and developing AI systems to make informed decisions. The algorithms employed by AI systems are capable of recognizing patterns and associations in medical images. These deep learning systems can be trained using given data to identify differences between cancerous and normal features by analyzing histopathologic whole tissue slides and radiologic records such as CT scans and MRI data. This ability makes AI systems an efficient tool for improving cancer diagnosis in various areas, including detecting the onset of disease, diagnosing tumors and their origins, and classifying and grading the cancer present. The full-text of their article is available for download here.

==========================================================================================================================================================================================================================================================================================
Genetics and pathophysiology of severe congenital neutropenias (SCNs)
Younesian et al. conducted a comprehensive review of current research examining the biological role of genes associated with the SCN and the effects of genetic mutations on the pathogenesis of neutropenia. Their primary objective was to elucidate the underlying mechanisms that contribute to the development of SCN-related disorders, with a particular emphasis on mutations in SCN1 to SCN9 and X-linked SCN (XSCN). The authors' detailed analysis sheds light on the complex interplay between genetic factors and disease pathophysiology.
The full-text of their article is available for download here, providing a valuable resource for further investigation into this important area of medical research.

 

Over the past few years, there has been an increasing focus on the potential of artificial intelligence (AI) to revolutionize the healthcare industry. One promising area of application is the use of AI-powered chatbots to enhance communication between patients and healthcare providers; the development of these chatbots represents a new and powerful tool for improving the quality and efficiency of healthcare communication.
The purpose of this Special Issue is to showcase original research and review articles that explore the latest advancements and emerging trends in the use of AI and chatbots in medical contexts. By highlighting the cutting-edge work being done in this field, this issue aims to advance our understanding of the potential of AI to transform healthcare delivery and improve patient outcomes.


 
              SUBMISSION DEADLINE: 10 October 2023

Journal Information

  • Journal Title:                                               Iranian Journal of Blood and Cancer
  • Publisher:                                                                            Iranian Pediatric Hematology & Oncology Society
  • Print ISSN:                                                                   2008-4595
  • Online ISSN:                                                                    2008-4609
  • Release interval:                                                              Quarterly
  • Journal language:                                                             English
  • Chairman:                                                                           Dr. Mohammad Saeid Rahiminejad
  • Editor-in-Chief:                                                              Dr. Hassan Abolghasemi
  • Associate Editors:                                                             Dr.Davood Bashash; Dr. Mohammad Faranoosh
  • Executive Editor:                                                          Amir-Mohammad Yousefi
  • Current Issue: 2023، Volume 15، Number 4

Newsletter subscription

Enter your email address to have site news and announcements delivered directly to your inbox.

CiteScore

Copyright Policy





This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

© 2023 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb